Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:FHTX NASDAQ:MLYS NASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$31.20-3.3%$30.09$23.23▼$42.29$1.00B0.64396,686 shs219,382 shsFHTXFoghorn Therapeutics$6.13+0.5%$4.67$2.94▼$10.25$341.69M3.05133,505 shs148,403 shsMLYSMineralys Therapeutics$14.23-0.8%$14.88$8.24▼$18.38$927.51M-0.3888,453 shs984,916 shsNTLAIntellia Therapeutics$12.06+1.9%$9.38$5.90▼$27.77$1.25B2.213.06 million shs3.83 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+1.54%-2.24%+9.58%+19.44%+1.00%FHTXFoghorn Therapeutics+3.74%+12.96%+27.35%+60.53%-4.24%MLYSMineralys Therapeutics+0.14%-2.05%+4.06%+7.42%+3.24%NTLAIntellia Therapeutics-1.09%-2.71%+23.49%+63.62%-56.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.4187 of 5 stars3.42.00.03.03.50.82.5FHTXFoghorn Therapeutics2.1194 of 5 stars3.60.00.00.03.31.70.6MLYSMineralys Therapeutics2.2283 of 5 stars3.41.00.00.01.94.20.0NTLAIntellia Therapeutics4.4155 of 5 stars4.31.00.04.71.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7540.22% UpsideFHTXFoghorn Therapeutics 3.13Buy$12.1397.80% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$32.25126.63% UpsideNTLAIntellia Therapeutics 2.65Moderate Buy$33.37176.69% UpsideCurrent Analyst Ratings BreakdownLatest FHTX, COLL, MLYS, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.006/16/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.006/16/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.006/3/2025NTLAIntellia TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $54.005/29/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $7.005/29/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.59$12.14 per share2.57$7.10 per share4.39FHTXFoghorn Therapeutics$22.60M15.12N/AN/A($0.82) per share-7.48MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ANTLAIntellia Therapeutics$57.88M21.58N/AN/A$8.56 per share1.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.2225.575.18N/A6.61%99.08%15.14%8/6/2025 (Estimated)FHTXFoghorn Therapeutics-$86.62M-$1.36N/AN/AN/A-342.23%N/A-27.28%8/6/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)Latest FHTX, COLL, MLYS, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025COLLCollegium Pharmaceutical$1.88N/AN/AN/A$182.26 millionN/A8/14/2025Q2 2025FHTXFoghorn Therapeutics-$0.32N/AN/AN/AN/AN/A8/14/2025Q2 2025NTLAIntellia Therapeutics-$1.03N/AN/AN/A$12.26 millionN/A8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78N/AN/AN/AN/AN/A5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.301.081.01FHTXFoghorn TherapeuticsN/A3.163.16MLYSMineralys TherapeuticsN/A26.4826.48NTLAIntellia TherapeuticsN/A4.904.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AFHTXFoghorn Therapeutics61.55%MLYSMineralys Therapeutics84.46%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%FHTXFoghorn Therapeutics7.58%MLYSMineralys Therapeutics25.56%NTLAIntellia Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableFHTXFoghorn Therapeutics12055.74 million51.52 millionOptionableMLYSMineralys Therapeutics2865.18 million48.52 millionOptionableNTLAIntellia Therapeutics600103.58 million100.37 millionOptionableFHTX, COLL, MLYS, and NTLA HeadlinesRecent News About These CompaniesWith Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'July 18 at 8:30 AM | seekingalpha.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 5.7% - Here's What HappenedJuly 16 at 1:00 PM | marketbeat.comGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (NTLA)...July 15 at 4:27 PM | marketbeat.comNTLA - Intellia Therapeutics Inc Trailing Returns - MorningstarJuly 12, 2025 | morningstar.comMMove Over, Magnificent 7: The Frontier 7 Will Redefine Our FutureJuly 10, 2025 | 247wallst.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6.1% - Should You Buy?July 8, 2025 | marketbeat.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 7, 2025 | globenewswire.comIntellia Gains 29.8% in a Month: How Should You Play the Stock?July 7, 2025 | zacks.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Eliana Clark Sells 1,022 SharesJuly 4, 2025 | insidertrades.comIntellia Therapeutics Inc. Advanced Charts | NTLA | Barron'sJuly 4, 2025 | barrons.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Sumitomo Mitsui Trust Group Inc.July 4, 2025 | marketbeat.comCitizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z DataJuly 3, 2025 | msn.comInsider Selling: Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $10,036.04 in StockJuly 3, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube Sells 2,503 SharesJuly 3, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Director Sells $14,278.81 in StockJuly 2, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6.8% - Here's WhyJuly 2, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 29, 2025 | marketbeat.comCRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - NasdaqJune 27, 2025 | nasdaq.comNTLA - Intellia Therapeutics Inc Chart - MorningstarJune 26, 2025 | morningstar.comMCRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?June 25, 2025 | zacks.comIntellia Therapeutics, Inc. (NTLA) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeConagra at Rock Bottom: 7% Yield & Turnaround PoisedBy Thomas Hughes | July 13, 2025View Conagra at Rock Bottom: 7% Yield & Turnaround Poised5 Hot Stocks With Summer Buybacks You Can Cash In OnBy Thomas Hughes | July 10, 2025View 5 Hot Stocks With Summer Buybacks You Can Cash In OnFHTX, COLL, MLYS, and NTLA Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$31.20 -1.06 (-3.29%) Closing price 04:00 PM EasternExtended Trading$31.20 0.00 (-0.02%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Foghorn Therapeutics NASDAQ:FHTX$6.13 +0.03 (+0.49%) Closing price 04:00 PM EasternExtended Trading$6.14 +0.01 (+0.16%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Mineralys Therapeutics NASDAQ:MLYS$14.23 -0.11 (-0.77%) Closing price 04:00 PM EasternExtended Trading$14.22 -0.01 (-0.04%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Intellia Therapeutics NASDAQ:NTLA$12.06 +0.23 (+1.94%) Closing price 04:00 PM EasternExtended Trading$12.06 0.00 (0.00%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
